{"title":"Triangulation evidence for the causal effect of monocytes on pulmonary artery hypertension: a Mendelian randomization study and results from NHANES","authors":"Zhekang Liu , Qingan Fu , Yijia Shao , Junda Cao","doi":"10.1016/j.rmed.2025.108388","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Previous research has indicated an association between circulating white blood cell (WBC) counts and the development of pulmonary arterial hypertension (PAH), however a causal relationship is unclear. This study aimed to investigate the causal link between circulating WBC counts and PAH.</div></div><div><h3>Methods</h3><div>We used the genome-wide association study (GWAS) datasets of European ancestry to perform Mendelian randomization to assess the effects of WBC counts on PAH. Summary statistics for WBC subtype counts were obtained from the Blood Cell Consortium, and data for PAH were sourced from FinnGen GWAS results. Furthermore, a cross-sectional observational study was conducted using data from the National Health and Nutrition Examination Survey (NHANES) to explore the relationship between WBC counts and PAH, involving a sample size of 15,835 participants.</div></div><div><h3>Results</h3><div>MR results showed that monocyte count was a risk factor for PAH (OR = 1.21, 95 % CI 1.05–1.40, P = 0.007), which was supported by a meta-analysis of IVW, and sensitivity analyses revealed the reliability of the MR results (OR = 1.21, 95 % CI 1.10–1.36, P = 0.0009). The association between monocyte count and PAH was also supported by a cross-sectional study based on NHANES.</div></div><div><h3>Conclusions</h3><div>This study shows a causal relationship between increased risk of PAH and monocyte counts, providing new insights into the role of monocytes in PAH. However, further studies are needed to validate this finding.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"248 ","pages":"Article 108388"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611125004512","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Previous research has indicated an association between circulating white blood cell (WBC) counts and the development of pulmonary arterial hypertension (PAH), however a causal relationship is unclear. This study aimed to investigate the causal link between circulating WBC counts and PAH.
Methods
We used the genome-wide association study (GWAS) datasets of European ancestry to perform Mendelian randomization to assess the effects of WBC counts on PAH. Summary statistics for WBC subtype counts were obtained from the Blood Cell Consortium, and data for PAH were sourced from FinnGen GWAS results. Furthermore, a cross-sectional observational study was conducted using data from the National Health and Nutrition Examination Survey (NHANES) to explore the relationship between WBC counts and PAH, involving a sample size of 15,835 participants.
Results
MR results showed that monocyte count was a risk factor for PAH (OR = 1.21, 95 % CI 1.05–1.40, P = 0.007), which was supported by a meta-analysis of IVW, and sensitivity analyses revealed the reliability of the MR results (OR = 1.21, 95 % CI 1.10–1.36, P = 0.0009). The association between monocyte count and PAH was also supported by a cross-sectional study based on NHANES.
Conclusions
This study shows a causal relationship between increased risk of PAH and monocyte counts, providing new insights into the role of monocytes in PAH. However, further studies are needed to validate this finding.
期刊介绍:
Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants.
Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.